Get the Stockscreener App
1.64
2.96%
-0.05
After Hours:
1.64
Macrogenics Inc stock is traded at $1.64, with a volume of 485.98K.
It is down -2.96% in the last 24 hours and up +3.14% over the past month.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
See More
Previous Close:
$1.69
Open:
$1.69
24h Volume:
485.98K
Relative Volume:
0.70
Market Cap:
$103.66M
Revenue:
$139.77M
Net Income/Loss:
$-97.62M
P/E Ratio:
-1.038
EPS:
-1.58
Net Cash Flow:
$-61.71M
1W Performance:
-6.82%
1M Performance:
+3.14%
6M Performance:
+27.13%
1Y Performance:
-60.39%
1-Day Range:
$1.635
$1.71
1-Week Range:
$1.635
$1.83
52-Week Range:
$0.9897
$5.10
Macrogenics Inc Stock (MGNX) Company Profile
Name
Macrogenics Inc
Sector
Industry
Phone
301-251-5172
Address
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
1.64 | 106.82M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Resumed | Barclays | Overweight |
| Nov-07-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Aug-01-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-31-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| May-10-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-10-24 | Downgrade | Stifel | Buy → Hold |
| May-10-24 | Downgrade | TD Cowen | Buy → Hold |
| Apr-26-24 | Initiated | B. Riley Securities | Buy |
| Apr-09-24 | Upgrade | TD Cowen | Hold → Buy |
| Mar-04-24 | Reiterated | BTIG Research | Buy |
| Feb-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-22-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-14-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-18-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Jul-11-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-04-22 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-28-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-04-22 | Initiated | SMBC Nikko | Outperform |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Upgrade | Barclays | Underweight → Overweight |
| Dec-22-20 | Resumed | H.C. Wainwright | Buy |
| Aug-03-20 | Downgrade | Citigroup | Buy → Neutral |
| Jun-01-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-26-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Dec-19-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-19 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-21-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Guggenheim | Neutral |
| Feb-07-19 | Upgrade | Citigroup | Sell → Buy |
| Feb-07-19 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-06-19 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-04-19 | Downgrade | Citigroup | Neutral → Sell |
| Dec-10-18 | Downgrade | Raymond James | Outperform → Underperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| May-31-18 | Initiated | Evercore ISI | Outperform |
| Mar-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-31-17 | Initiated | Raymond James | Outperform |
View All
Macrogenics Inc Stock (MGNX) Latest News
Chart based analysis of MacroGenics Inc. trends2025 Volume Leaders & Expert Curated Trade Ideas - newser.com
Will MacroGenics Inc. stock rally after Fed decisions2025 Short Interest & Consistent Profit Alerts - newser.com
Can MacroGenics Inc. stock hit record highs againEarnings Overview Report & Long-Term Growth Portfolio Plans - newser.com
When is the best time to exit MacroGenics Inc.July 2025 Momentum & Low Risk High Reward Trade Ideas - newser.com
Applying Wyckoff theory to MacroGenics Inc. stock2025 Investor Takeaways & Daily Entry Point Trade Alerts - newser.com
Weiss Ratings Reaffirms Sell (E+) Rating for MacroGenics (NASDAQ:MGNX) - MarketBeat
Bispecific Antibodies MarketGlobal Forecast 2025-2032, Profiles of Key PlayersF. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab - Yahoo Finance
Public Employees Retirement System of Ohio Has $31,000 Stake in MacroGenics, Inc. $MGNX - Defense World
MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
MacroGenics (NASDAQ:MGNX) and CeriBell (NASDAQ:CBLL) Head to Head Comparison - Defense World
Regression analysis insights on MacroGenics Inc. performanceDay Trade & Weekly Market Pulse Updates - newser.com
Using data models to predict MacroGenics Inc. stock movementJuly 2025 Spike Watch & Low Risk Profit Maximizing Plans - newser.com
Published on: 2025-10-05 06:01:39 - newser.com
Backtesting results for MacroGenics Inc. trading strategies2025 EndofYear Setup & Daily Risk Controlled Trade Plans - newser.com
Multi asset correlation models including MacroGenics Inc.Quarterly Profit Review & Weekly Breakout Stock Alerts - newser.com
How currency fluctuations impact MacroGenics Inc. stockJuly 2025 Breakouts & Expert Approved Momentum Trade Ideas - newser.com
Developing predictive dashboards with MacroGenics Inc. dataWeekly Investment Report & Verified Entry Point Signals - newser.com
Published on: 2025-10-02 22:14:22 - newser.com
Voya Investment Management LLC Buys 40,500 Shares of MacroGenics, Inc. $MGNX - Defense World
Published on: 2025-09-30 05:12:41 - newser.com
What drives MacroGenics Inc stock priceCash Flow Trends & Amplify Gains With Picks - earlytimes.in
Goldman Sachs Group Inc. Has $251,000 Position in MacroGenics, Inc. $MGNX - MarketBeat
Extensive-Stage Small Cell Lung Cancer Pipeline 2025: Innovative Clinical Developments By 25+ Global Leaders Delveinsight Key Companies Featured Include Shanghai Henlius Biotech, Macrogenics, Inc. - Menafn.com
What drives PROG Holdings Inc AZD stock priceInterest Rate Changes & Small Capital Wealth Plans - earlytimes.in
*DJ Macrogenics Announces Removal of Partial Clinical Hold on MGD009 Program by FDA >MGNX - 富途牛牛
Strs Ohio Invests $263,000 in MacroGenics, Inc. $MGNX - MarketBeat
Intraday pattern recognizer results for MacroGenics Inc.July 2025 PostEarnings & Real-Time Volume Analysis - newser.com
Statistical indicators supporting MacroGenics Inc.’s strengthIPO Watch & Accurate Entry and Exit Point Alerts - newser.com
Published on: 2025-09-22 05:42:18 - newser.com
Barclays Upgrades MacroGenics (NASDAQ:MGNX) to "Strong-Buy" - MarketBeat
MacroGenics (NASDAQ:MGNX) Now Covered by Analysts at Barclays - MarketBeat
Acadian Asset Management LLC Grows Position in MacroGenics, Inc. $MGNX - MarketBeat
Live market analysis of MacroGenics Inc.Quarterly Market Summary & Safe Capital Allocation Plans - newser.com
What institutional flow reveals about MacroGenics Inc.July 2025 Drop Watch & Capital Efficient Trade Techniques - newser.com
Momentum divergence signals in MacroGenics Inc. chartProfit Target & Weekly Market Pulse Alerts - newser.com
What indicators show strength in MacroGenics Inc.Weekly Investment Report & Free Growth Oriented Trading Recommendations - newser.com
Using economic indicators to assess MacroGenics Inc. potential2025 Trading Volume Trends & Safe Entry Zone Identification - newser.com
MacroGenics Inc. stock trend outlook and recovery pathDay Trade & Daily Technical Stock Forecast Reports - newser.com
Macrogenics Inc Stock (MGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Macrogenics Inc Stock (MGNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HEIDEN WILLIAM K | Director |
Aug 20 '25 |
Buy |
1.49 |
49,500 |
73,755 |
111,000 |
| Koenig Scott | Director |
Aug 13 '25 |
Option Exercise |
0.00 |
52,829 |
0 |
830,244 |
| Bonvini Ezio | Sr VP, Research & CSO |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
124,414 |
| Karrels James | SVP, CFO and Secretary |
Feb 15 '25 |
Option Exercise |
0.00 |
14,998 |
0 |
192,591 |
| Koenig Scott | President and CEO |
Feb 15 '25 |
Option Exercise |
0.00 |
42,329 |
0 |
777,415 |
| Peters Jeffrey Stuart | Senior VP and General Counsel |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
18,858 |
| Risser Eric Blasius | Chief Operating Officer |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
62,422 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Option Exercise |
0.00 |
1,095 |
0 |
9,955 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Sale |
2.56 |
423 |
1,083 |
9,532 |
| Spitznagel Thomas | Sr VP, Technical Ops |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
26,922 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):